Terumo Aortic announces launch and first commercial use of the Aortic Balloon device
The device assists physicians in the expansion of the aorta when using TREO and RELAY stent-grafts in endovascular aortic repair. Complementing our market leading product range of surgical and endovascular grafts, the Aortic Balloon is a low profile device with 10 F and offers exceptional inflation control and the broadest balloon diameter range, up to […]
Terumo Aortic announces PMDA Approval and first commercial implant of TREO endovascular device in Japan
This first implant was undertaken by Takao Ohki, MD, Chairman of the Department of Surgery, Professor and Chief of the Division of Vascular Surgery, Jikei University School of Medicine, Tokyo. Professor Ohki commented: “The procedure was very successful, the device performed well, and the patient is making a good recovery. The major concerns in endovascular […]
Terumo Aortic announces publication of the primary endpoint results from the TREO Pivotal Study
Following recent approval by the US Food and Drug Administration (FDA) of the TREO® Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the publication of the primary endpoint results from the investigational device exemption (IDE) pivotal study in the Journal of Vascular Surgery.
Terumo Creates Global Group Music
The composition is based on the concept “Let’s respect the past, dream for the future, and open new doors together.” The track is composed by Mr. Akira Senju, a highly regarded Japanese composer and recipient of numerous awards and honors. Mr. Senju’s 35th anniversary album which was released on October 21 includes ‘TOGETHER’, one of […]
Terumo Aortic announces US FDA Approval for TREO endovascular device
TREO is the only device commercially available for endovascular aneurysm repair (EVAR) with dual proximal fixation and lock stent technology offering physicians the next advancement in endovascular device solutions. It is a three-piece design featuring in situ limb adjustability and provides a wide range of aortic device configurations to specifically address the anatomy of each […]
Terumo Aortic Announces US FDA Breakthrough Device designation for Thoraflex Hybrid device
The purpose of the FDA’s Breakthrough Device Designation program is to fast-track the regulatory review process for certain medical technologies and device-led combination products that satisfy certain criteria; these include providing a more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The aim of the program is to provide patients and […]
Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide
TOKYO, JAPAN – April 22, 2020 – As the world joins together to support healthcare workers and others on the front lines providing critical care to patients, Terumo Corporation (TSE: 4543) is donating USD 2.4 million in cash and products to support the novel coronavirus disease (COVID-19) relief efforts worldwide – including a USD 1 […]
Terumo acquires Aortica Corporation
Terumo Corporation (TSE: 4543) today announced that it has decided to acquire Aortica Corporation, a U.S.-based company dedicated to advancing the science of personalised vascular therapy. Aortica has developed an automated case planning software known as AortaFit™, designed to precisely match fenestrations on an endograft with the unique locations of each individual patient’s branch arteries […]
Terumo Aortic announces completion of enrolment of Relay®Pro US pivotal study
RelayPro is a low profile, next generation thoracic stent graft device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels. RelayPro, having obtained CE Mark in 2018, utilises the same stent design, material and dual sheath technology already proven in Terumo Aortic’s Relay®Plus device, with the additional […]
Terumo Aortic announces launch of industry-first global endovascular registry
TiGER is a global, prospective, multi-arm, multi-centre registry evaluating more than 1,000 patients over a period of 5 years. The study will collect a broad range of clinical evidence on the company’s comprehensive thoracic and abdominal endovascular product portfolio. At the recent European Investigators’ Meeting, the TiGER Principal Investigator, Professor Vincent Riambau, Barcelona commented, “This […]
